UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
May
2, 2005
Date of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
State
of New York |
1-10113 |
11-0853640 |
(State
of Other Jurisdiction of Incorporation) |
(Commission
File Number) |
(I.R.S.
Employer Identification Number) |
616 N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including are code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
Item
2.02 Results
of Operations and Financial Condition
On May 2,
2005, Acura Pharmaceuticals, Inc. (the "Company") issued a press release
disclosing the financial results for its first quarter ended March 31, 2005. A
copy of the Company's press release is attached as Exhibit 99.1
hereto.
Item
9.01 Financial
Statements and Exhibits.
|
Exhibit |
|
|
Number |
Description |
| |
|
|
99.1 |
Press
Release dated May 2, 2005 Announcing Results for First Quarter ended March
31, 2005. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
|
|
| |
ACURA
PHARMACEUTICALS, INC. |
|
|
|
| |
By: |
/s/ Peter A. Clemens |
| |
Peter A. Clemens |
| |
Vice President & Chief
Financial Officer |
Date: May 2,
2005
EXHIBIT
INDEX
|
Exhibit |
|
|
Number |
Description |
| |
|
|
99.1 |
Press
|